← Back to Search

IDH2 Inhibitor

Enasidenib for Clonal Cytopenia

Phase 1
Waitlist Available
Led By Eytan Stein, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 18 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing whether a drug called enasidenib can improve blood cell counts in people with clonal cytopenia of undetermined significance (CCUS).

Who is the study for?
Adults over 18 with clonal cytopenia of undetermined significance (CCUS) and IDH2 gene mutation can join this trial. They must have had unexplained low blood counts for at least 6 months, be in fair health, and able to follow the study plan. Pregnant women or those with active cancer, recent malignancy history, certain infections or conditions affecting drug absorption cannot participate.
What is being tested?
The trial is testing Enasidenib's safety and effectiveness on CCUS by blocking a mutated protein that may improve blood cell counts. Participants will take Enasidenib orally to see if it helps increase their white blood cells, platelets, and hemoglobin levels.
What are the potential side effects?
Enasidenib might cause side effects like jaundice due to high bilirubin levels in some cases; however specific side effects are not listed here but generally could include digestive issues, liver enzyme changes, fatigue or allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 18 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Best Response

Side effects data

From 2023 Phase 2 trial • 6 Patients • NCT04281498
50%
Anemia
50%
White blood cell decreased
50%
Headache
50%
Hyperuricemia
50%
Epistaxis
50%
Aspartate aminotransferase increased
50%
Platelet count decreased
50%
Blood bilirubin increased
33%
Dyspnea
33%
Hyperkalemia
33%
Constipation
33%
Edema limbs
33%
Fever (Pyrexia)
33%
Bone pain
33%
Neutrophil count decreased
33%
Creatinine increased
33%
Leukocytosis
33%
Hypocalcemia
17%
Vertigo
17%
Bruising
17%
Fatigue
17%
Abdominal pain
17%
Alkaline phosphatase increased
17%
Belching
17%
Fall
17%
Hypertension
17%
Nasal congestion
17%
OTHER Unspecified contact dermatitis
17%
Oral pain
17%
Back pain
17%
Hyperphosphatemia
17%
OTHER Ear lobe pain
17%
Alanine aminotransferase increased
17%
Anorexia
17%
Bloating
17%
Heart failure
17%
Hypokalemia
17%
Dizziness
17%
OTHER COVID-19
17%
Skin hyperpigmentation
17%
Upper respiratory infection
17%
Hypermagnesemia
17%
Hypernatremia
17%
OTHER early satiety
17%
OTHER Night sweats
17%
OTHER Petechial
17%
Febrile neutropenia
17%
Muscle cramp
17%
OTHER Heartburn
100%
80%
60%
40%
20%
0%
Study treatment Arm
Patients With MPN

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants with CCUS with mutations in IDH2Experimental Treatment1 Intervention
Participants will have CCUS with mutations in IDH2
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Enasidenib
2020
Completed Phase 2
~610

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,979 Previous Clinical Trials
600,074 Total Patients Enrolled
Eytan Stein, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
2 Previous Clinical Trials
48 Total Patients Enrolled

Media Library

Enasidenib (IDH2 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05102370 — Phase 1
Clonal Cytopenia Research Study Groups: Participants with CCUS with mutations in IDH2
Clonal Cytopenia Clinical Trial 2023: Enasidenib Highlights & Side Effects. Trial Name: NCT05102370 — Phase 1
Enasidenib (IDH2 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05102370 — Phase 1
~1 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top